PNP-PC child development: milestones, autism screening, ADHD, and neurodevelopmental assessment

Developmental surveillance includes four domains: gross motor, fine motor, language/communication, and personal-social. Delays in any single domain require referral to appropriate specialist; delays in ≥2 domains (global developmental delay) require comprehensive neuropsychological evaluation.

Key milestone ages for PNP-PC certification:

• 2 months: Social smile (responds to face), coos (vowel sounds), tracks 180°, lifts head 45° in prone
• 4 months: Laughs aloud, hands to midline, reaches for objects, holds head steady
• 6 months: Sits with support (tripod), rolls both ways, transfers objects hand to hand, babbles (consonant-vowel — "baba", "dada")
• 9 months: Sits independently, crawls, pincer grasp (9–12 months), says "mama/dada" nonspecifically, stranger anxiety
• 12 months: Walks with support or independently (range 9–15 months), 2–3 words besides mama/dada, points, waves bye-bye, follows simple 1-step commands
• 18 months: Walks independently, 10–25 words, uses spoon, stacks 4 blocks, symbolic play begins
• 24 months: Runs, ≥50 words, 2-word phrases, kicks ball, parallel play, follows 2-step instructions
• 3 years: Pedals tricycle, climbs stairs with alternating feet, 3-word sentences, names friends, toilet training completed (most children)
• 4–5 years: Hops, skips, catches ball, draws person with 6+ parts, knows first and last name and age, cooperative play, may read some letters/words

ASD prevalence: ~1 in 36 children in the US (CDC 2023). More common in males (4:1 ratio). Significant racial/ethnic disparities in diagnosis timing (Black, Hispanic children diagnosed later).

M-CHAT-R/F (Modified Checklist for Autism in Toddlers): PEDS-recommended at 18 and 24 months (USPSTF evidence insufficient, but AAP recommends). M-CHAT-R alone has high false-positive rate; positive screen requires follow-up (F) interview to confirm. Positive M-CHAT-RF: refer for comprehensive ASD evaluation AND early intervention simultaneously (do not wait for diagnosis).

DSM-5 ASD criteria: Persistent deficits in social communication across multiple contexts (social-emotional reciprocity, nonverbal communication, relationships) AND restricted/repetitive behaviours (stereotyped movements, insistence on sameness, highly restricted interests, sensory hyper/hyporeactivity). Symptoms present in early developmental period. Three severity levels (1–3) based on support needed.

Management: No pharmacological cure. Evidence-based interventions: Applied Behaviour Analysis (ABA) — most studied; early intensive (20–40 hours/week) most effective for improving outcomes in young children. Speech-language therapy, occupational therapy, social skills training. Pharmacotherapy for comorbidities: aripiprazole and risperidone FDA-approved for irritability associated with ASD; methylphenidate/amphetamines for comorbid ADHD. Early diagnosis and early intervention (before age 3) produce the best outcomes — neuroplasticity window.